Antimicrobial Resistance: The Global Threat of Superbugs and Future Solutions

Antimicrobial resistance (AMR) has emerged as one of the most critical global public health and development threats of the 21st century. This phenomenon occurs when microorganisms—including bacteria, fungi, parasites, and viruses—undergo evolutionary processes that render them resistant to the medications used to treat them, such as antibiotics.

The scale of the crisis is reflected in global mortality data. In 2019, bacterial AMR was directly responsible for 1.27 million deaths worldwide and contributed to an additional 4.95 million deaths.

Drivers of Resistance

The development of drug-resistant pathogens is primarily driven by the misuse and overuse of antimicrobials across three main sectors: humans, animals, and plants.

While AMR affects all countries regardless of region or income level, the consequences are exacerbated by inequality and poverty. Low- and middle-income countries are the most severely affected by these drivers.

Impact on Modern Medicine and Economy

AMR jeopardizes many of the advancements made in modern medicine by making common infections harder to treat. This increased resistance makes essential medical procedures significantly riskier, including:

• Surgery
• Caesarean sections
• Cancer chemotherapy

Beyond the clinical impact, the economic burden is substantial. The World Bank estimates that AMR could lead to US$ 1 trillion in additional healthcare costs by 2050. It is projected that gross domestic product (GDP) losses could range from US$ 1 trillion to US$ 3.4 trillion per year by 2030.

The Pipeline and Access Crisis

The global health community is currently facing a dual crisis regarding the antibiotics pipeline and access. There is an inadequate research and development pipeline to keep pace with rising resistance levels.

There is an urgent need for measures that ensure equitable access to existing and new diagnostics, vaccines, and medicines to mitigate the spread of superbugs, which are microorganisms resistant to most known antimicrobials.

Public Health Priorities

To address AMR within human health, priorities include preventing all infections that could lead to the inappropriate use of antimicrobials and ensuring universal access to quality diagnosis and appropriate treatment.

Strategic innovation is also critical, specifically in the following areas:

• Surveillance of antimicrobial consumption and use.
• Surveillance of AMR.
• Research and development for novel medicines, diagnostics, and vaccines.

Antimicrobials encompass a broad range of medicines used to treat infectious diseases, including antibiotics, antivirals, antifungals, and antiparasitics.